Neogenomics (NEO) Free Cash Flow (2010 - 2026)

Neogenomics (NEO) has reported Free Cash Flow for 17 consecutive years, with -$13.1 million the latest figure, recorded in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$13.1 million, up 55.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.2 million (up 162.96% YoY), and the FY2025 annual result was $3.5 million, down 41.51% from the prior year.
• Free Cash Flow was -$13.1 million for Q1 2026 at Neogenomics, down from $18.8 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $38.2 million in Q4 2024 and troughed at -$37.3 million in Q1 2022.
• Average Free Cash Flow over 5 years is -$4.3 million, with a median of -$1.6 million recorded in 2024.
• Year-over-year, Free Cash Flow slumped 28982.95% in 2022 and jumped 1620.76% in 2025.
• Over 5 years, Free Cash Flow stood at $21.0 million in 2022, then retreated by 15.13% to $17.8 million in 2023, then surged by 114.77% to $38.2 million in 2024, then slumped by 50.94% to $18.8 million in 2025, then slumped by 170.0% to -$13.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$13.1 million in Q1 2026, $18.8 million in Q4 2025, and $570000.0 in Q3 2025.